tiprankstipranks
Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Holding ATOS?
Track your performance easily

Atossa Therapeutics (ATOS) Income Statement

2,141 Followers

Atossa Therapeutics Income Statement

Last quarter (Q3 2024), Atossa Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Atossa Therapeutics's net income was $-7.23M. See Atossa Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 29.49M$ 31.38M$ 27.69M$ 20.52M$ 14.61M$ 17.27M
Operating Income
$ -29.49M$ -31.38M$ -27.69M$ -20.52M$ -14.61M$ -17.27M
Net Non Operating Interest Income Expense
$ 4.45M$ 4.34M$ 877.00K$ 6.00K--
Other Income Expense
$ 1.87M$ 3.07M$ -146.00K$ 91.00K$ 2.28M$ -25.65K
Pretax Income
$ -26.91M$ -30.09M$ -26.96M$ -20.61M$ -17.83M$ -17.24M
Tax Provision
$ -2.00K$ -2.00K----
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -26.94M$ -30.10M$ -26.96M$ -20.61M$ -22.33M$ -17.24M
Basic EPS
$ -0.22$ -0.24$ -0.21$ -0.18$ -1.97-
Diluted EPS
$ -0.22$ -0.24$ -0.21$ -0.18$ -1.97$ -2.03
Basic Average Shares
$ 502.11M$ 126.08M$ 126.62M$ 116.95K$ 11.31M$ 8.50M
Diluted Average Shares
$ 502.11M$ 126.08M$ 126.62M$ 116.95K$ 11.31M$ 8.50M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 29.49M$ 31.38M$ 27.69M$ 20.52M$ 14.61M$ 17.27M
Net Income From Continuing And Discontinued Operation
$ -26.94M$ -30.10M$ -26.96M$ -20.61M$ -17.83M$ -17.24M
Normalized Income
$ -25.01M-----
Interest Expense
------
EBIT
$ -26.91M$ -30.11M$ -27.69M$ -20.52M$ -14.61M$ -17.24M
EBITDA
$ -26.88M$ -30.08M$ -27.68M$ -20.50M$ -14.56M$ -17.19M
Currency in USD

Atossa Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis